Article

Biodegradable dexamethasone implant shows good results for macular edema

New Orleans-A biodegradable implant containing dexamethasone (Posurdex, Allergan) showed significant improvements in best-corrected visual acuity at a dose of 700 micrograms compared with 350 microns and observation, reported Julie Haller, MD, at the annual meeting of the American Academy of Ophthalmology.

Three hundred six patients with persistent macular edema were randomized to either 350 micrograms (n = 100), 700 micrograms (101), or observation (n = 105). Most of the study patients had either diabetic retinopathy (n = 165) or central or branch retinal vein occlusion (n = 102). The device was surgically implanted into a sclerectomy.

Dr. Haller from Baltimore reported that at 90 days after implantation the 700-microgram dose outperformed the lower dose and observation in the degree of increased visual acuity, decreased retinal thickness, and decreased leakage. The IOP increased in 17% of the eyes that received the 700-microgram dose and in 12% of the eyes that received the 35-microgram dose, but later decreased. There was no increase in the progression of cataract in any eyes.

"The implant achieved the primary efficacy outcome with the 700-microgram dose in that there was a significant greater than 3 line improvement in vision 180 days after implantation. There was a clear dose-related response, and there were no safety issues associated with the implant," Dr. Haller said.

The phase III trial is starting. In this phase, the device will be implanted into the vitreous base using an applicator.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.